• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Gemini Therapeutics Inc.

    9/25/23 4:56:23 PM ET
    $GMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMTX alert in real time by email
    SC 13G 1 tm2326849d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. ____)*

     

     

    Disc Medicine, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    254604101

    (CUSIP Number)

     

    September 14, 2023

    (Date of Event Which Requires Filing of this statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 10 Pages 

     

    CUSIP No. 254604101

      

    1.Names of Reporting Persons

     

    Paradigm BioCapital Advisors LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH REPORTING
    PERSON WITH: 

    5. SOLE VOTING POWER 1,235,918
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER  1,235,918
    8. SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,235,918

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.4%

     

    12.Type of Reporting Person (See Instructions)

     

    PN

       

     

    *       The information above is given as of the end of business on September 25, 2023, the filing date of this Schedule 13G.

     

     Page 2 of 10 Pages 

     

    CUSIP No. 254604101

     

    1.Names of Reporting Persons

     

    Paradigm BioCapital Advisors GP LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH REPORTING
    PERSON WITH: 

    5. SOLE VOTING POWER 1,235,918
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 1,235,918
    8. SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,235,918

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.4%

     

    12.Type of Reporting Person (See Instructions)

     

    OO 

     

     

    *       The information above is given as of the end of business on September 25, 2023, the filing date of this Schedule 13G.

     

     Page 3 of 10 Pages 

     

    CUSIP No. 254604101

     

    1.Names of Reporting Persons

     

    Senai Asefaw, M.D.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    United States of America

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH REPORTING
    PERSON WITH: 

    5. SOLE VOTING POWER 1,235,918
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER  1,235,918
    8. SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,235,918

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.4%

     

    12.Type of Reporting Person (See Instructions)

     

    IN 

      

     

    *       The information above is given as of the end of business on September 25, 2023, the filing date of this Schedule 13G.

     

     Page 4 of 10 Pages 

     

    CUSIP No. 254604101

     

    1.Names of Reporting Persons

     

    Paradigm BioCapital International Fund Ltd.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH REPORTING
    PERSON WITH: 

    5. SOLE VOTING POWER 1,030,317
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER  1,030,317
    8. SHARED DISPOSITIVE POWER 0

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,030,317

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    4.5%

     

    12.Type of Reporting Person (See Instructions)

     

    CO  

     

     

    *       The information above is given as of the end of business on September 25, 2023, the filing date of this Schedule 13G.

     

     Page 5 of 10 Pages 

     

     

    Item 1.

     

    (a)The name of the issuer is Disc Medicine, Inc. (the “Issuer”).

     

    (b)The principal executive offices of the Issuer are located at 321 Arsenal Street, Suite 101, Watertown, MA 02472.

     

    Item 2.

     

    (a)This Schedule 13G is filed by the following (the “Reporting Persons”): (1) Paradigm BioCapital Advisors LP (the “Adviser”); (2) Paradigm BioCapital Advisors GP LLC (the “Adviser GP”); (3) Senai Asefaw, M.D. (“Senai Asefaw”); and (4) Paradigm BioCapital International Fund Ltd. (the “Fund”). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the “Account”) directly beneficially own the Common Stock (as defined below) reported in this Statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.

     

    (b)The principal business office of the Reporting Persons is 767 Third Avenue, 17th Floor, New York, NY 10017.

     

    (c)For citizenship information see Item 4 of the cover page of each Reporting Person.

     

    (d)This statement relates to the Common Stock, $0.0001 par value per share, of the Issuer (the “Common Stock”).

     

    (e)The CUSIP Number of the Common Stock is 254604101.

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);

     

     Page 6 of 10 Pages 

     

     

    (g) o A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) o Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:______________________

     

    Item 4. Ownership.

     

    See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on September 25, 2023, the date of filing of this Schedule 13G.

     

    As of the close of business on the Event Date of September 14, 2023, the Reporting Persons collectively beneficially owned 1,143,882 shares of Common Stock (938,281 of which was held by the Fund and 205,601 of which was held by the Account), representing 5.0% of all of the outstanding shares of Common Stock.

     

    The percentages of beneficial ownership contained herein are based on 22,877,552 shares of Common Stock outstanding as of August 8, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 11, 2023.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ⃣

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

     Page 7 of 10 Pages 

     

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    (a)Not applicable.

     

    (b)Not applicable.

     

    (c)By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     Page 8 of 10 Pages 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: September 25, 2023

     

    Paradigm BioCapital Advisors LP

    Paradigm BioCapital Advisors GP LLC

    Paradigm BioCapital International Fund Ltd.

     

    By:   /s/ David K. Kim  

    Name: David K. Kim

    Title: Authorized Signatory

     

     

    /s/ Senai Asefaw, M.D.  

    Senai Asefaw, M.D.

     

     Page 9 of 10 Pages 

     

     

    EXHIBIT INDEX

     

     

    Exhibit No. Document
       
    1 Joint Filing Agreement

     

     Page 10 of 10 Pages 

    Get the next $GMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMTX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $2.00Buy → Neutral
    HC Wainwright & Co.
    3/3/2022$10.00 → $2.00Outperform → Market Perform
    SVB Leerink
    3/1/2022$23.00 → $1.50Buy → Hold
    Jefferies
    1/24/2022$15.00 → $10.00Outperform
    SVB Leerink
    12/20/2021$25.00 → $15.00Outperform
    SVB Leerink
    12/15/2021$20.00Buy
    HC Wainwright & Co.
    10/6/2021$20.00 → $18.00Buy
    Goldman Sachs
    More analyst ratings

    $GMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Gemini Therapeutics downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Gemini Therapeutics from Buy to Neutral and set a new price target of $2.00 from $5.00 previously

      3/11/22 6:36:28 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Gemini Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $10.00 previously

      3/3/22 6:29:25 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Gemini Therapeutics from Buy to Hold and set a new price target of $1.50 from $23.00 previously

      3/1/22 6:13:52 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

      WATERTOWN, Mass., Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the U.S. Food and Drug Administration ("FDA") granted Orphan Drug Designation to bitopertin for the treatment of erythropoietic protoporphyria ("EPP"). Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 ("GlyT1") designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX ("PPIX"), the toxic metabolite that causes dise

      12/27/22 8:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

      WATERTOWN, Mass., Dec. 13, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients living with serious hematologic diseases, presented five posters spanning several of its hematology programs at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition held in New Orleans, LA. "Disc Medicine continues to make considerable progress towards the development of potentially first-in-class therapeutic candidates for hematologic disorders," said John

      12/13/22 9:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

      CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that five abstracts related to several of its hematology programs have been accepted for poster presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, LA on December 10-13, 2022.  "We are pleased to have five abstracts selected for presentat

      11/3/22 9:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    SEC Filings

    See more
    • Gemini Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Disc Medicine, Inc. (0001816736) (Filer)

      2/7/24 8:10:55 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Gemini Therapeutics Inc.

      144 - Disc Medicine, Inc. (0001816736) (Subject)

      1/23/24 5:47:19 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Gemini Therapeutics Inc.

      144 - Disc Medicine, Inc. (0001816736) (Subject)

      1/23/24 5:44:49 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Gemini Therapeutics Provides Corporate Update

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company's current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company. Additionally, the Company has initiated a process to evaluate strategic alternatives in order

      2/28/22 8:30:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company's Board of Directors. "I am pleased to welcome Georges to Gemini's Board of Directors during this important time in our Company's maturation, as we advance our lead program into the next stages of clinical development," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "Georges' broad management experience and proven track record of commercial and product development success wi

      5/3/21 7:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini's Chief Medical Officer, effective immediately. "We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist specializing in the treatment of retinal and macular diseases," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "As we continue to advance our clinical pipeline, we will benefit tremendously from his two-plus deca

      4/12/21 8:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Franchi Jean M. was granted 36,666 shares (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      2/15/24 8:37:53 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Franchi Jean M.

      3 - Disc Medicine, Inc. (0001816736) (Issuer)

      2/15/24 8:33:28 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bitterman Kevin sold $6,934,125 worth of shares (102,500 units at $67.65) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      1/25/24 4:33:04 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/14/24 4:08:06 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/13/24 6:51:49 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/9/24 8:50:22 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care